ANVS Stock Summary and Trading Ideas (Annovis Bio | NYSE:ANVS)

Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Annovis Bio trades on the NYSE stock market under the symbol ANVS.

As of January 29, 2025, ANVS stock price climbed to $4.89 with 148,215 million shares trading.

ANVS has a beta of 3.81, meaning it tends to be more sensitive to market movements. ANVS has a correlation of 0.08 to the broad based SPY ETF.

ANVS has a market cap of $67.47 million. This is considered a Micro Cap stock.

In the last 3 years, ANVS traded as high as $23.91 and as low as $4.21.

The top ETF exchange traded funds that ANVS belongs to (by Net Assets): VTI, VXF, IWC.

ANVS has underperformed the market in the last year with a return of -50.7%, while the SPY ETF gained +24.9%. In the last 3 month period, ANVS fell short of the market, returning -49.6%, while SPY returned +4.0%. However, in the most recent 2 weeks ANVS has outperformed the stock market by returning +4.7%, while SPY returned +3.4%.

ANVS support price is $4.63 and resistance is $5.09 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANVS shares will trade within this expected range on the day.